ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Alvotech (ALVO) shares have significantly underperformed, down 38% year-to-date and trading near a 52-week low, primarily due to intense biosimilar competition and tariff concerns. Despite this market sentiment, the company reported robust operational growth, with product revenue surging 200% to $205 million in H1 2025, driven by key biosimilar sales, alongside strategic expansions into new therapeutic areas and partnerships. While the stock trades at a premium, improved EPS estimates suggest analysts see future growth potential, leading to a "Hold" recommendation amidst a highly competitive landscape.

Analysis

Alvotech (ALVO) presents a significant disconnect between its recent stock performance and underlying operational momentum. Shares have declined 38% year-to-date, trading near a 52-week low and below key moving averages, a stark underperformance against the industry's 5% growth. This price action is attributed to investor concerns regarding intense competition in the biosimilar space and potential pharmaceutical import tariffs. However, fundamentally, the company is executing strongly. Product revenue surged over 200% year-over-year in the first half of 2025 to $205 million, propelled by sales of its Simlandi and Selarsdi biosimilars. Management has affirmed its full-year 2025 revenue guidance of $600-$700 million, suggesting confidence in sustained growth. Strategically, Alvotech is expanding its pipeline through a de-risked partnership model, recently gaining EU approval for Mynzepli (an Eylea biosimilar) and initiating development for five new candidates, including biosimilars for Keytruda and Kesimpta. Despite this progress, the stock trades at a premium to the industry with a price-to-sales ratio of 3.32, and competitive pressures remain a key risk to margins. Counterbalancing this valuation concern are the significant upward revisions to 2025 and 2026 EPS estimates over the past 30 days, indicating growing analyst conviction in the company's earnings power.

Key Decisions for Investors

• Investors should weigh the stark contrast between the negative share price momentum, driven by sector-wide competitive fears, and the company's robust fundamental execution, including 200% revenue growth and a strong sales outlook.
• Monitor near-term pipeline catalysts, as expected year-end regulatory approvals for biosimilars to Prolia/Xgeva and Simponi could serve to rerate the stock and validate its growth trajectory.
• Given the premium valuation relative to the industry, a disciplined approach is warranted; consider the current 'Hold' stance, and await further confirmation of sustained commercial execution or a more favorable entry point before building a significant position.